The "Total Therapy" program, developed at the University of Arkansas for Medical Sciences (UAMS), is an intensive, multi-phase treatment strategy specifically designed for myeloma. It was pioneered by Dr. Bart Barlogie and has evolved through several versions (Total Therapy 1, 2, 3, and beyond).
The approach combines Show Full Answer
The "Total Therapy" program, developed at the University of Arkansas for Medical Sciences (UAMS), is an intensive, multi-phase treatment strategy specifically designed for myeloma. It was pioneered by Dr. Bart Barlogie and has evolved through several versions (Total Therapy 1, 2, 3, and beyond).
The approach combines several treatments in a coordinated sequence, including:
- Induction chemotherapy (multiple drug combinations)
- Tandem autologous stem cell transplants (two transplants back-to-back)
- Consolidation chemotherapy
- Maintenance therapy
The goal is to achieve the deepest possible remission — ideally a complete response or even minimal residual disease (MRD) negativity — by hitting the myeloma hard from multiple angles at once. As for whether it's "better," the answer isn't straightforward. Here's what's generally understood:
- For younger, fit patients, Total Therapy has shown impressive deep remission rates and, in some cases, prolonged survival
- The tandem transplant component remains debated — some studies show benefit, others suggest a single transplant with strong maintenance works just as well for many patients
- It is a very intensive regimen, which means side effects and treatment burden are significant
- Not every myeloma center uses this approach, and many achieve excellent outcomes with less intensive strategies tailored to the individual
The "best" approach really depends on factors like age, overall health, genetic risk profile of the myeloma, and personal preferences around treatment intensity. It's worth having a detailed conversation with a myeloma specialist — ideally at a center with high myeloma volume — to weigh the options for a specific situation.
May 25
Join
Your Privacy Choices
